Current therapeutic approaches for cancer, e.g., monochemotherapy targeting KRAS mutations and a combination of chemotherapy with radiotherapy/immunotherapy, have exhibited limited efficacy in patients with PDAC (31). Here, KRAS is linked to cancer.